Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00659529 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease

A Phase 1 study of Cystic Fibrosis, sponsored by National Jewish Health.

Completed
Registry status
Phase 1
Development phase
36
Enrollment target
1
Study location

NCT00659529 is a Phase 1 study of Cystic Fibrosis that has completed, run by National Jewish Health. The registered enrollment target is 36 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00659529, a Phase 1 study of Cystic Fibrosis, has completed, sponsored by National Jewish Health.

COMPLETED
Registry status
Phase 1
Development phase
36 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether sildenafil can decrease inflammation in CF lung disease.

Conditions Studied

Interventions

  • DRUG sildenafil

Study Locations (1)

Colorado

  • National Jewish Health - Denver

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2008-08
Est. Completion 2012-12
Phase Phase 1

Sponsor

National Jewish Health

83 total trials

What the Registry Record Tells You About NCT00659529

The ClinicalTrials.gov registry entry for NCT00659529 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (80% lower). The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which sildenafil is the first listed.

NCT00659529 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.

Frequently Asked Questions

What is clinical trial NCT00659529 about?

NCT00659529 is a clinical study titled "Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung Disease". The purpose of this study is to determine whether sildenafil can decrease inflammation in CF lung disease.

What is the current status of trial NCT00659529?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2008-08. Estimated completion is 2012-12.

What conditions does trial NCT00659529 study?

This clinical trial studies the following conditions: Cystic Fibrosis.

What interventions are being tested in trial NCT00659529?

The interventions under investigation include: sildenafil (DRUG).

Who is sponsoring clinical trial NCT00659529?

This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00659529 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.